Pharmacy Compounding Regulation in the German Pharmaceutical Market. Part 2. Organisational Features (Review)
https://doi.org/10.30895/1991-2919-2024-590
Abstract
INTRODUCTION. The Russian Federation has decided to restore the system of compounding pharmacies as an element of the critical national healthcare infrastructure and pharmaceutical supply chain. To improve Russian regulatory practices, develop novel advanced approaches to pharmacy compounding and quality control, and implement these approaches, it is necessary to study relevant good compounding practices applied in healthcare systems of other countries.
AIM. This study aimed to analyse the German experience in the organisation and regulation of pharmaceutical compounding to suggest recommendations for the development and implementation of Russian guidelines on good compounding and dispensing practices.
DISCUSSION. This work continues a comprehensive study that delves into the current provisions of German legislation governing the system of good compounding practices. This article examines the differences between approaches to compounding by medical and pharmaceutical specialists. According to the findings, compounding by medical specialists is guided by the “free practice of medicine” principle and is subject to minimal regulatory oversight. All pharmacy organisations operate as compounding pharmacies, thereby enhancing the physical accessibility of compounded medicinal products to the population. The authors highlight the features of a process-based quality assurance system encompassing production process controls and quality control methods for compounded medicinal products. Additionally, the authors discuss the applicability of rapid test methods to compounding. In accordance with the German concept of good pharmacy practices, a compounding pharmacy may use the available validation, qualification, and verification tools in the pharmaceutical development of compounded medicinal products and may outsource its internal quality control function. Using the concept of risk ranking, compounding pharmacies may design their own sampling programmes. The article describes approaches to and requirements for organising the evaluation of compounding prescriptions. In Germany, compounding pharmacies may independently assign shelf lives to the compounded medicinal products they produce.
CONCLUSIONS. Some German solutions are of considerable practical importance and are applicable to the development and implementation of Russian guidelines on good compounding and dispensing practices. In particular, pharmacy organisations may outsource the quality control of their compounded medicinal products. Additionally, pharmacies can conduct the full-scale pharmaceutical development of compounding technologies and quality control methods (including rapid test methods) using the validation, qualification, and verification tools available to drug manufacturers. Moreover, pharmacy organisations may independently assign shelf lives to the compounded medicinal products they produce. Finally, pharmacy organisations may design their individual sampling programmes.
About the Authors
S. E. Erdni-GaryaevRussian Federation
Sergey E. Erdni-Garyaev
14A Professor Popov St., St Petersburg 197376
D. D. Mamedov
Russian Federation
Devi D. Mamedov
14A Professor Popov St., St Petersburg 197376
D. S. Yurochkin
Russian Federation
Dmitry S. Yurochkin
14A Professor Popov St., St Petersburg 197376
D. D. Zelikova
Russian Federation
Daria D. Zelikova
14A Professor Popov St., St Petersburg 197376
Z. M. Golant
Russian Federation
Zakhar M. Golant, Cand. Sci. (Econ.)
14A Professor Popov St., St Petersburg 197376
V. S. Fisenko
Russian Federation
Victor S. Fisenko, Cand. Sci. (Pharm.)
3 Rakhmanovsky Ln., City Service Post Office-4, Moscow 127994
I. A. Narkevich
Russian Federation
Igor A. Narkevich, Dr. Sci. (Pharm.), Professor
14A Professor Popov St., St Petersburg 197376
References
1. Erdni-Garyaev SE, Mamedov DD, Yurochkin DS, Zelikova DD, Golant ZM, Fisenko VS, Narkevich IA. Pharmacy compounding regulation in the German pharmaceutical market. Part 1. Basic regulatory provisions (Review). Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2024;14(1):91–109 (In Russ.). https://doi.org/10.30895/1991-2919-2024-14-1-91-109
2. Narkevich IA, Fisenko VS, Golant ZM, Yurochkin DS, Mamedov DD, Erdni-Garyaev SE, Leshkevich AA. Basis for forming a unified harmonized system of regulation in the field of compounding pharmacies. St. Petersburg: Mediapapier; 2023 (In Russ.). EDN: PZEVDF
3. Farrakhov AZ, Solomatina TV, Mamedov DD, Yurochkin DS, Golant ZM, Narkevich IA. Fundamentals of forming a strategy for the development of the segment of manufacturing and dispensing of medicines in the Russian Federation. Vestnik Roszdravnadzora. 2023;(6):6–17 (In Russ.). EDN: NAHOAC
4. Bouwman-Boer Y, Fenton-May V, Le Brun P, eds. Practical pharmaceutics. An international guideline for the preparation, care and use of medicinal products. Cham, Switzerland: Springer; 2015. https://doi.org/10.1007/978-3-319-15814-3
Supplementary files
![]() |
1. Table 1. Example of assigning shelf life to starting materials in a German pharmacy organisation | |
Subject | ||
Type | Исследовательские инструменты | |
Download
(909KB)
|
Indexing metadata ▾ |
![]() |
2. Table 2. Maximum shelf life for some compounded dosage forms in Germany | |
Subject | ||
Type | Исследовательские инструменты | |
Download
(933KB)
|
Indexing metadata ▾ |
![]() |
3. Table 3. Risk assessment decision criteria | |
Subject | ||
Type | Исследовательские инструменты | |
Download
(926KB)
|
Indexing metadata ▾ |
![]() |
4. Table 4. Risk categories and internal quality control examples | |
Subject | ||
Type | Исследовательские инструменты | |
Download
(1MB)
|
Indexing metadata ▾ |
![]() |
5. Table 5. Risk-assessment form for stock preparations according to the German Drug Codex and New German Formulary (Deutscher Arzneimittel-Codex / Neues Rezeptur-Formularium) | |
Subject | ||
Type | Исследовательские инструменты | |
Download
(815KB)
|
Indexing metadata ▾ |
![]() |
6. Table 6. Comparison of the manufacturing costs for stock preparations and extemporaneous formulations using the example of compounding 20 packages of 0.1–50.0% betamethasone valerate hydrophilic cream (Deutscher Arzneimittel-Codex / Neues Rezeptur-Formularium (DAC/NRF), formulation NRF 11.37.), in 2019 prices | |
Subject | ||
Type | Исследовательские инструменты | |
Download
(1MB)
|
Indexing metadata ▾ |
![]() |
7. Fig. 1. Flowchart for compounding extemporaneous formulations | |
Subject | ||
Type | Исследовательские инструменты | |
Download
(1MB)
|
Indexing metadata ▾ |
![]() |
8. Fig. 2. Flowchart for compounding stock preparations | |
Subject | ||
Type | Исследовательские инструменты | |
Download
(1MB)
|
Indexing metadata ▾ |
Review
For citations:
Erdni-Garyaev S.E., Mamedov D.D., Yurochkin D.S., Zelikova D.D., Golant Z.M., Fisenko V.S., Narkevich I.A. Pharmacy Compounding Regulation in the German Pharmaceutical Market. Part 2. Organisational Features (Review). Regulatory Research and Medicine Evaluation. 2025;15(1):63-81. (In Russ.) https://doi.org/10.30895/1991-2919-2024-590